Skip to main content
main-content

Melanoma and skin cancers

News and opinion

13-02-2019 | Checkpoint blockade | News

Immune checkpoint inhibitors viable in advanced cancer complicated by HIV

Immune checkpoint inhibitor therapy is well tolerated by patients with HIV infection and advanced-stage cancer and does not appear to adversely affect HIV viral load or CD4 cell count, suggest results of a systematic data review.

28-01-2019 | Immunotherapy | Podcast | Audio

Understanding the relationship between the gut microbiome and immunotherapy

Jennifer Wargo, from The University of Texas MD Anderson Cancer Center in Houston, USA, shares her insights into recent research showing an association between intestinal microbiota and response to immunotherapy (13:27).

28-01-2019 | Melanoma | Editorial | Article

IDO inhibitors in advanced melanoma: A path forward?

On the back of success in melanoma with PD-1 and CTLA-4 checkpoint inhibitors, attention has turned to other checkpoint proteins such as indoleamine 2,3-dioxygenase (IDO). In this editorial, Zeynep Eroglu (Moffitt Cancer Center, USA) discusses the advances and setbacks in the development of IDO inhibitors for melanoma.

12-12-2018 | Immunotherapy | Feature | Article

Hyperprogression as a response to immunotherapy: ‘A serious downside’

In light of recent reports of hyperprogression in response to treatment with cancer immunotherapy, medwireNews spoke to medical oncologist Razelle Kurzrock (University of California, San Diego, La Jolla, USA) about the phenomenon, the implications for therapy, and future directions for research.

21-11-2018 | Checkpoint blockade | News

Specific cardiovascular toxicities associated with immune checkpoint inhibitor use

Patients treated with immune checkpoint inhibitors are at increased risk for cardiovascular immune-related adverse events including those associated with myocarditis, pericardial disease, and vasculitis, suggests an analysis of the WHO pharmacovigilance database.

01-11-2018 | Immunotherapy | ESMO 2018 | News

Anti-PD-1 immunotherapy feasible for patients with HIV and cancer

A database analysis reported at the ESMO 2018 Congress in Munich, Germany, points to the feasibility of using immune checkpoint inhibitors in people living with HIV who develop cancer.

30-10-2018 | Melanoma | ESMO 2018 | News

Continued benefits of immunotherapy shown in advanced melanoma

An updated analysis of the CheckMate 067 trial shows continued survival benefits at 4 years with nivolumab plus ipilimumab or nivolumab monotherapy versus ipilimumab alone in patients with previously untreated advanced melanoma.

18-10-2018 | Melanoma | News

Neoadjuvant checkpoint blockade investigated in high-risk melanoma

In patients with high-risk resectable melanoma, neoadjuvant treatment with the combination of nivolumab and ipilimumab is associated with high response rates but also considerable toxicity, while single-agent nivolumab has better tolerability but is less efficacious, trial results show.

02-10-2018 | FDA | News

First advanced cutaneous squamous cell carcinoma drug approved

Read more on this US FDA announcement here

14-09-2018 | EMA | News

EMA supports encorafenib plus binimetinib combination

Read more here

07-09-2018 | Metastatic melanoma | News

FDG-PET predicts metastatic melanoma outcomes better than CT imaging

Using 18F-fluorodeoxyglucose–positron emission tomography to measure treatment response at 1 year in patients with metastatic melanoma may better predict long-term outcomes than standard computed tomography, research shows.

23-08-2018 | Targeted therapy | News

New molecular target classification system could aid treatment decision making

The ESMO Translational Research and Precision Medicine Working Group has proposed a classification system that orders the value of molecular aberrations as oncologic clinical targets based on the supporting evidence available.

16-08-2018 | Skin cancers | News

Brief dermatologist-delivered intervention may improve sun protection behavior

The Addressing Behavior Change intervention, which can be delivered by dermatologists in less than 3 minutes, is associated with improvements in people’s sun protection behavior that last several months, findings indicate.

10-08-2018 | Bevacizumab | News

Adjuvant bevacizumab not recommended for melanoma, HER2-negative breast cancer

The AVAST-M and E5103 trial results rule out the use of bevacizumab in the adjuvant setting in high-risk patients with cutaneous melanoma and HER2-negative breast cancer, respectively.

17-07-2018 | Melanoma | News

‘Dramatically improved’ OS with checkpoint inhibitor use for melanoma brain metastases

Melanoma patients with brain metastases can expect to live longer following the incorporation of checkpoint inhibitors and BRAF-targeted therapies into standard care than their counterparts treated prior to the approval of these agents, suggests an analysis of the US National Cancer Database.

12-07-2018 | Ipilimumab | News

High glucocorticoid doses may negatively impact CTLA-4 inhibitor efficacy

Researchers recommend against the routine use of high-dose glucocorticoids for the treatment of ipilimumab-induced hypophysitis inpatients with melanoma after observing poorer oncologic outcomes with high versus low doses.

05-07-2018 | FDA | News

Encorafenib–binimetinib approved for BRAF-mutated advanced melanoma

Find out more about this US FDA decision here

18-06-2018 | Melanoma | ASCO 2018 | News

COLUMBUS OS data favor encorafenib–binimetinib for advanced BRAF-mutated melanoma

An updated analysis of the phase III COLUMBUS trial adds to the evidence supporting a combination of the BRAF inhibitor encorafenib and the MEK inhibitor binimetinib in patients with advanced BRAF V600-mutant melanoma.

medwireNews@ASCO2018

COLUMBUS OS data favor encorafenib–binimetinib for advanced BRAF-mutated melanoma

An updated analysis of the phase III COLUMBUS trial adds to the evidence supporting a combination of the BRAF inhibitor encorafenib and the MEK inhibitor binimetinib in patients with advanced BRAF V600-mutant melanoma.

04-06-2018 | Risk factors | News

Elevated cancer risk in psoriatic arthritis patients undergoing treatment

Individuals receiving treatment for psoriatic arthritis may have an increased risk for developing cancer, a meta-analysis indicates.

image credits